Management of Systemic Sclerosis with Active Skin, Joint, and Lung Involvement

First‑Line Immunosuppressive Therapy

Mycophenolate mofetil (MMF) is the preferred initial agent for patients with active systemic sclerosis affecting skin, joints, and interstitial lung disease (ILD). The 2023 EULAR recommendations designate MMF as the novel first‑line intervention for active skin fibrosis and SSc‑ILD, citing its ability to soften skin, modify disease trajectory, and address pulmonary involvement. Strong recommendation (high‑quality evidence). 1
MMF is recommended over cyclophosphamide as the first‑line immunosuppressant for both skin and lung manifestations. Evidence from a 2023 review (Nature Reviews Rheumatology) supports MMF’s superiority in efficacy and safety compared with cyclophosphamide. Conditional recommendation. 2
Methotrexate (≈25 mg weekly) may be used when MMF is not tolerated or when musculoskeletal disease predominates, but evidence for its effect on joint disease is limited. The citation notes the paucity of robust data despite some improvement in skin scores. Weak recommendation. 1

Nintedanib should be added when ILD remains fibrotic and progressive despite adequate MMF therapy, particularly if forced vital capacity (FVC) falls below 80 % of predicted. This reflects guidance from the American Thoracic Society (ATS) on combining antifibrotic and immunosuppressive strategies. Strong recommendation (high‑quality evidence). 1
Pirfenidone is an alternative antifibrotic agent for SSc‑ILD, although the supporting evidence is less robust than for nintedanib. Conditional recommendation. 2

Rituximab (anti‑CD20) is incorporated into the 2023 EULAR recommendations as a novel option for treating skin fibrosis and SSc‑ILD. Conditional recommendation. 1
Tocilizumab (anti‑IL‑6) is similarly recommended by EULAR for patients who fail to achieve adequate response to MMF. Conditional recommendation. 1

AHSCT should be considered for patients with very high‑risk features (e.g., modified Rodnan skin score > 24 or moderate skin disease with worsening ILD despite conventional immunosuppression). Evidence shows improved survival in early diffuse cutaneous systemic sclerosis with high skin scores or progressive ILD. Conditional recommendation (expert consensus). 2

Dihydropyridine calcium‑channel blockers (e.g., nifedipine) are first‑line for Raynaud phenomenon. Strong recommendation (clinical practice guideline). 2
Phosphodiesterase‑5 inhibitors or intravenous iloprost are recommended when calcium‑channel blockers are insufficient. Conditional recommendation. 2
Bosentan reduces the incidence of new digital ulcers in systemic sclerosis. Conditional recommendation. 2

There is a lack of high‑quality evidence that corticosteroids, tocilizumab, or rituximab improve joint manifestations in systemic sclerosis. The 2025 Annals of the Rheumatic Diseases article highlights this uncertainty. Evidence level: low. 1
Abatacept has shown mixed results: case series suggest benefit for joint disease, but a phase‑2 trial did not demonstrate significant differences in swollen or tender joint counts at 12 months, despite some improvement in functional scores. Evidence level: moderate to low. 1

The European League Against Rheumatism recommends mycophenolate mofetil (MMF) as the first-line treatment for scleroderma with positive skin biopsy, regardless of SCL-70 antibody status, to address both skin thickening and potential interstitial lung disease 3, 4, 5
MMF has surpassed cyclophosphamide as the initial treatment of choice and is the most commonly prescribed first-line drug for skin manifestations in diffuse cutaneous SSc (dcSSc), with a mean mRSS improvement of -4.90 points 3, 4

The American College of Rheumatology suggests methotrexate 25 mg per week as an alternative first-line treatment if MMF is not tolerated or if musculoskeletal involvement is predominant, with approximately 5-point improvement in mRSS 3, 6

The European Respiratory Society recommends pulmonary function tests (PFTs) with DLCO to detect subclinical ILD, and high-resolution CT (HRCT) of the chest as the primary tool to diagnose ILD 4, 5
The American Heart Association recommends echocardiogram to screen for pulmonary arterial hypertension, and blood pressure monitoring to establish baseline for scleroderma renal crisis surveillance 4, 6

The European League Against Rheumatism advises against corticosteroids as monotherapy, as they are associated with substantial long-term morbidity in fibrotic lung disease, and increase risk of scleroderma renal crisis in early diffuse cutaneous SSc 5, 6
If disease progresses on MMF, consider rituximab (anti-CD20) or tocilizumab (anti-IL-6) as second-line options, and if ILD is fibrotic and progressing despite immunosuppression, add nintedanib as antifibrotic therapy 3, 4, 5, 6

The American College of Rheumatology recommends serial PFTs every 3-6 months to track forced vital capacity (FVC), and repeat HRCT at defined intervals to assess fibrosis progression 3, 5
Monitor mRSS at each visit to quantify skin improvement, and watch for progression indicators: worsening dyspnea, declining FVC >10%, or new HRCT changes 3, 5

The European League Against Rheumatism recommends dihydropyridine calcium channel blockers (especially nifedipine) as first-line for Raynaud, and phosphodiesterase 5 inhibitors or intravenous iloprost if calcium channel blockers insufficient 4, 6